Focused On-demand Library for Thyroid receptor-interacting protein 11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q15643

UPID:

TRIPB_HUMAN

Alternative names:

Clonal evolution-related gene on chromosome 14 protein; Golgi-associated microtubule-binding protein 210; Trip230

Alternative UPACC:

Q15643; B2RUT2; O14689; O15154; O95949; Q6MZL5

Background:

Thyroid receptor-interacting protein 11, also known as Golgi-associated microtubule-binding protein 210, plays a pivotal role in vesicle tethering to Golgi, crucial for Golgi structure and function. It facilitates both anterograde and retrograde trafficking in the early secretory pathway, impacting ER-to-Golgi and Golgi complex operations. Additionally, it binds the thyroid receptor in the presence of triiodothyronine, enhancing transcription.

Therapeutic significance:

Linked to diseases such as Achondrogenesis 1A and Odontochondrodysplasia 1, which involve skeletal and dental development issues, understanding the role of Thyroid receptor-interacting protein 11 could open doors to potential therapeutic strategies.